Keywords: Psoriasis, USA, Dermatologusts, Pfizer, Tofacitinib, Celgene, Apremilast, Decision Resources

46% of US dermatologists expect to prescribe Pfizer’s tofacitinib to psoriasis patients who failed one biologic

Article | 17 November 2011

Print This

In the first year following its approval for psoriasis, nearly one-half (46%) of surveyed dermatologists in the USA expect to prescribe ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in